Literature DB >> 19948572

Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease.

Josep Figueras-Aloy1, José M Rodríguez-Miguélez, Martin Iriondo-Sanz, María-Dolores Salvia-Roiges, Francesc Botet-Mussons, Xavier Carbonell-Estrany.   

Abstract

OBJECTIVE: The objective of this study was to assess whether the use of high-dose intravenous immunoglobulin (IVIG) in late-preterm and term newborns with severe isoimmune hemolytic jaundice caused by Rh and ABO incompatibility was a risk factor for necrotizing enterocolitis (NEC).
METHODS: An observational, retrospective study that encompassed 16 years was conducted. A total of 492 liveborn infants who were of >or=34 weeks' gestation and had severe isoimmune hemolytic jaundice caused by Rh (n = 91) and ABO (n = 401) incompatibility and were treated with phototherapy were included in the study. IVIG (500 mg/kg over 2-4 hours) was indicated when total serum bilirubin level plus 2 points reached 85% of the cutoff value for performing exchange transfusion.
RESULTS: A total of 167 (34%) infants received IVIG. NEC was diagnosed in 11 (2.2%) patients: 10 (6%) in the IVIG-treated group and 1 (0.3%) in the non-IVIG-treated group. Five patients required urgent operation, and 1 of them died as a result of massive intestinal necrosis. Another patient died 2 years later as a result of short bowel syndrome. In the multivariate analysis, cesarean delivery (odds ratio [OR]: 3.76 [95% confidence interval (CI): 1.10-12.90), Apgar test at 5 minutes (OR: 0.50 [95% CI: 0.40-0.64), and IVIG (OR: 31.66 [95% CI: 3.25-308.57]) were independent factors significantly associated with NEC.
CONCLUSIONS: The use of high-dose IVIG for severe isoimmune hemolytic jaundice in late-preterm and term infants was associated with a higher incidence of NEC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948572     DOI: 10.1542/peds.2009-0676

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial.

Authors:  Mohsen Saleh Elalfy; Nancy Samir Elbarbary; Heba Wegdan Abaza
Journal:  Eur J Pediatr       Date:  2010-10-06       Impact factor: 3.183

2.  Improving the management and outcome in haemolytic disease of the foetus and newborn.

Authors:  Enrico Lopriore; Mirjam E A Rath; Helen Liley; Vivianne E H J Smits-Wintjens
Journal:  Blood Transfus       Date:  2013-07-19       Impact factor: 3.443

3.  A Doppler velocimetry evaluation of intestinal blood flow characteristics in neonates receiving intravenous immunoglobulin therapy: a prospective observational study.

Authors:  Deepak Louis; Sandeep Patil; Shiv Sajan Saini; Praveen Kumar
Journal:  Indian J Pediatr       Date:  2015-01-20       Impact factor: 1.967

Review 4.  Necrotizing enterocolitis risk: state of the science.

Authors:  Sheila M Gephart; Jacqueline M McGrath; Judith A Effken; Melissa D Halpern
Journal:  Adv Neonatal Care       Date:  2012-04       Impact factor: 1.968

5.  Innate Immunity in the Small Intestine of the Preterm Infant.

Authors:  Steven J McElroy; Jörn-Hendrik Weitkamp
Journal:  Neoreviews       Date:  2011-09-01

6.  Mapping the New World of Necrotizing Enterocolitis (NEC): Review and Opinion.

Authors:  Phillip Gordon; Robert Christensen; Jörn-Hendrik Weitkamp; Akhil Maheshwari
Journal:  EJ Neonatol Res       Date:  2012

7.  Comparison of outcomes of group O vs non-group O premature neonates receiving group O RBC transfusions.

Authors:  Leonard I Boral; Zane G Staubach; Reny de Leeuw; Duncan C Macivor; Richard Kryscio; Henrietta S Bada
Journal:  Am J Clin Pathol       Date:  2013-12       Impact factor: 2.493

8.  Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven.

Authors:  S A Pasman; L Claes; L Lewi; D Van Schoubroeck; A Debeer; M Emonds; E Geuten; L De Catte; R Devlieger
Journal:  Facts Views Vis Obgyn       Date:  2015

9.  Maternal, fetal and perinatal factors associated with necrotizing enterocolitis in Sweden. A national case-control study.

Authors:  Margareta Ahle; Peder Drott; Anders Elfvin; Roland E Andersson
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

Review 10.  Immunoglobulin for alloimmune hemolytic disease in neonates.

Authors:  Carolien Zwiers; Mirjam Ea Scheffer-Rath; Enrico Lopriore; Masja de Haas; Helen G Liley
Journal:  Cochrane Database Syst Rev       Date:  2018-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.